Clinical Trials
14 trialsNCT07405086 2026-05-22
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 4 Recruiting
NCT07574047 2026-05-07
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
Swiss Cancer Institute
Phase 4 Not yet recruiting
NCT05522660 2026-04-27
USZ-STRIKE
ETOP IBCSG Partners Foundation
Phase 3 Recruiting
NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT07428252 2026-02-25
Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma
Institute of Oncology Ljubljana
Phase NA Active not recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT06052852 2025-11-17
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase 1 Terminated
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT04625205 2025-04-06
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
BioNTech SE
Phase 1 Terminated
NCT03504488 2025-01-15
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
BioAtla, Inc.
Phase 1/2 Completed
NCT05878977 2024-10-18
Biomarkers in Immunotherapy of Melanoma
Institute of Oncology Ljubljana
Phase NA Recruiting
NCT03511391 2024-01-23
CHEERS
University Hospital, Ghent
Phase 2 Completed
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT02574533 2017-09-27
Pilot Study of Vigilâ„¢ + Pembrolizumab for Advanced Melanoma
Gradalis, Inc.
Phase 1 Completed